Spots Global Cancer Trial Database for Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Official Title: Prospective Study of Melastatin Expression in Predicting the Risk for Developing Local Regional Metastases of Primary Melanoma
Study ID: NCT00049010
Conditions
Study Description
Brief Summary: RATIONALE: Diagnostic procedures that analyze surgically-removed tumor tissue and lymph node samples may help doctors identify patients with melanoma who are at risk for developing metastatic cancer. PURPOSE: This clinical trial is studying tumor tissue and lymph node samples to see how well they work in predicting the development of metastatic cancer in patients with stage I or stage II melanoma.
Detailed Description: OBJECTIVES: * Correlate degree of melastatin gene expression with risk of developing local regional metastases in patients with primary stage I or II melanoma. * Correlate melastatin expression prospectively with event-free survival of these patients. OUTLINE: This is a multicenter study. Melastatin mRNA expression is determined by in situ hybridization using tissue from primary tumor and lymph nodes. Tissue is also examined by immunohistochemical staining using antibodies to S-100 and MART-1. Patients do not receive the results of these tests nor do the results influence individual therapy. Patients are followed every 4 months for 3.5 years. PROJECTED ACCRUAL: A total of 300 patients will be accrued for this study within 3.5 years.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Chicago Cancer Research Center, Chicago, Illinois, United States
Iowa Blood and Cancer Care, Cedar Rapids, Iowa, United States
St. Luke's Hospital, Cedar Rapids, Iowa, United States
Mercy Regional Cancer Center at Mercy Medical Center, Cedar Rapids, Iowa, United States
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Brigham and Women's Hospital, Boston, Massachusetts, United States
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
Commonwealth Hematology-Oncology P.C. - Worcester, Worcester, Massachusetts, United States
Fairview University Medical Center - University Campus, Minneapolis, Minnesota, United States
Ellis Fischel Cancer Center at University of Missouri - Columbia, Columbia, Missouri, United States
Capital Region Cancer Center, Jefferson City, Missouri, United States
Kingsbury Center for Cancer Care at Cheshire Medical Center, Keene, New Hampshire, United States
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States
Charles R. Wood Cancer Center at Glens Falls Hospital, Glens Falls, New York, United States
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
CCOP - Hematology-Oncology Associates of Central New York, Syracuse, New York, United States
Community General Hospital of Greater Syracuse, Syracuse, New York, United States
Wayne Memorial Hospital, Incorporated, Goldsboro, North Carolina, United States
Wayne Radiation Oncology, Goldsboro, North Carolina, United States
Wilson Medical Center, Wilson, North Carolina, United States
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
Rhode Island Hospital, Providence, Rhode Island, United States
Miriam Hospital at Lifespan, Providence, Rhode Island, United States
Roper St. Francis Cancer Center at Roper Hospital, Charleston, South Carolina, United States
Mountainview Medical, Berlin, Vermont, United States
Fletcher Allen Health Care - University Health Center Campus, Burlington, Vermont, United States
Danville Regional Medical Center, Danville, Virginia, United States
Contact Details
Name: F. Stephen Hodi, MD
Affiliation: Dana-Farber Cancer Institute
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
